AI assistant
Black Diamond Therapeutics, Inc. — Director's Dealing 2023
Sep 18, 2023
33652_dirs_2023-09-18_d0eb3f1a-ec59-4e65-81c4-e50a05890168.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Black Diamond Therapeutics, Inc. (BDTX)
CIK: 0001701541
Period of Report: 2023-09-15
Reporting Person: Velleca Mark A. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-09-15 | Common Stock | A | 5208 | $3.60 | Acquired | 46522 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-09-17 | Stock Option (Right to Buy) | $3.55 | A | 1000000 | Acquired | 2033-09-16 | Common Stock (1000000) | Direct |
Footnotes
F1: These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 14, 2023.
F3: 25% of the shares subject to this option shall vest and become exercisable on September 17, 2024, with the remainder vesting in 36 equal monthly installments thereafter.